|
J Biol Chem, Vol. 273, Issue 37, 24239-24248, September 11, 1998
Transcriptional Regulatory Patterns of the Myelin Basic Protein
and Malic Enzyme Genes by the Thyroid Hormone Receptors 1 and
1*
Elisabeth
Jeannin,
Daniel
Robyr, and
Béatrice
Desvergne
From the Institut de Biologie Animale, Université de
Lausanne, Bâtiment de Biologie,
CH-1015 Lausanne, Switzerland
 |
ABSTRACT |
While there is evidence that the two ubiquitously
expressed thyroid hormone (T3) receptors, TR 1 and TR 1, have
distinct functional specificities, the mechanism by which they
discriminate potential target genes remains largely unexplained. In
this study, we demonstrate that the thyroid hormone response elements
(TRE) from the malic enzyme and myelin basic protein genes
(METRE and MBPTRE) respectively, are not
functionally equivalent. The METRE, which is a direct repeat motif with a 4-base pair gap between the two half-site hexamers
binds thyroid hormone receptor as a heterodimer with 9-cis-retinoic acid receptor (RXR) and mediates a high
T3-dependent activation in response to TR 1 or TR 1 in
NIH3T3 cells. In contrast, the MBPTRE, which consists of an
inverted palindrome formed by two hexamers spaced by 6 base pairs,
confers an efficient transactivation by TR 1 but a poor
transactivation by TR 1. While both receptors form heterodimers with
RXR on MBPTRE, the poor transactivation by TR 1
correlates also with its ability to bind efficiently as a monomer. This
monomer, which is only observed with TR 1 bound to
MBPTRE, interacts neither with N-CoR nor with SRC-1,
explaining its functional inefficacy. However, in Xenopus
oocytes, in which RXR proteins are not detectable, the transactivation
mediated by TR 1 and TR 1 is equivalent and independent of a RXR
supply, raising the question of the identity of the thyroid hormone
receptor partner in these cells. Thus, in mammalian cells, the binding characteristics of TR 1 to MBPTRE (i.e. high
monomer binding efficiency and low transactivation activity) might
explain the particular pattern of T3 responsiveness of MBP gene
expression during central nervous system development.
 |
INTRODUCTION |
Thyroid hormone receptors
(TRs)1 are transcription
factors that belong to the steroid/thyroid nuclear receptor
superfamily, which are encoded by two distinct genes,
c-erbA and c-erbA . Alternative splicing of
the gene primary transcripts at their 3' extremity generates
mRNAs encoding TR 1, which binds thyroid hormone
(triiodothyronine; T3), as well as the c-erbA 2 and
c-erbA 3 variants, which do not. The gene expresses
two T3-binding isoforms, TR 1 and the minor form TR 2 (reviewed in
Ref. 1). In the adult animal, the 1 and 1 receptor mRNAs are
found in all T3-sensitive tissues, albeit with differences in their
relative abundance (2, 3). In contrast, expression of the two receptor
isotypes is strikingly different during brain development. Whereas
TR 1 expression predominates at early stages and remains steady,
TR 1 expression is initially very low but exhibits a dramatic
transient increase during the critical period of the central nervous
system maturation (4-6). At this moment, 1 transcripts prevail in
the proliferation layer, while those of 1 are localized in the
differentiation layer of the developing rat cerebral cortex. These
patterns of expression are consistent with specific functions of the
two receptors in brain development (7-9).
TR transactivation activities are mediated through binding to specific
DNA elements called thyroid hormone response elements (TREs) present in
the promoter of target genes. TREs are composed of two hexameric
half-sites closely related to the consensus AGGTCA, arranged either as
a direct repeat (DR), or as palindromic or inverted palindromic (IP)
arrays (10). An intriguing feature of TRs is their ability to interact
with these TREs as monomer, homodimer, or heterodimer with the
9-cis-retinoic acid receptor (RXR). The relatively high
binding affinity of the TR/RXR heterodimer for the TREs (11-17), the
broad expression of RXR (18-20), and the requirement of RXR for
in vitro ligand-dependent transcription by TRs
(21) emphasize the predominant role of this heterodimer in
transcription activation. In contrast, the role of TR homodimers that
are disrupted upon T3 addition in in vitro binding assays (22-24) and that of TR monomers whose binding requires an extended TRE
half-site are not yet elucidated. The recent identification of nuclear
receptor co-repressors and co-activators suggests that TR-mediated
transcriptional regulation is a stepwise process. It is thought that,
in the absence of T3, TR/RXR binds to the TRE and represses basal
promoter activity by interacting with silencing factors such as N-CoR
and SMRT (25, 26). The addition of T3 would release co-repressors,
thereby allowing the interaction of the receptors with co-activators
such as SRC-1 and p300/CBP (27, 28). Thus, transactivation of target
genes would consist of both a derepression and then a further
stimulation of the target promoter.
While there is evidence for specific roles of TR 1 and TR 1 in
mediating T3 effects as mentioned above, the mechanism by which the two
receptors discriminate between specific target genes remains largely
unexplained. To address this question, we analyzed two T3-regulated
genes, the malic enzyme (ME) and the myelin basic protein (MBP) genes.
The ME gene is involved in lipid metabolism, more particularly in lipid
synthesis. Its expression is ubiquitous but is up-regulated by T3 in
rat liver, kidney, and heart. So far, no specific developmental
expression pattern of this gene has been described. The product of the
second gene studied herein, MBP, is a major protein constituent of the
myelin sheet surrounding the axons. Expression of this gene is nervous
system-specific and developmentally regulated. Up-regulation by T3 is
mainly observed during the high myelinating activity at the critical
period of brain maturation (29). Interestingly, the onset of
myelination is marked by transiently elevated levels of TR 1 mRNA
that parallel those of MBP mRNA, suggesting the involvement of
TR 1 in the regulated expression of the MBP gene (30). Moreover, when
analyzed in a reporter gene transfection assay, TR 1 is a more potent
T3-dependent inducer of the MBP promoter activity than
TR 1. In contrast, the ME promoter is more efficiently stimulated by
TR 1 as compared with TR 1 in response to T3 (31). This
differential regulation of these two genes by TR 1 and TR 1 is thus
physiologically relevant and provides a model to gain insight into the
mechanisms of TR isotype-specific action.
In this study, we demonstrate that in NIH3T3 cells the TREs of the ME
and MBP genes (METRE and MBPTRE) are not
functionally equivalent. The METRE, which is a direct
repeat motif with a 4-base pair gap between two hexamers (DR4, Fig.
1A) (32), mediates high T3-dependent response by
both TR 1 and TR 1. In contrast, the MBPTRE, which
consists of an inverted palindrome formed by two hexamers spaced by 6 base pairs (IP6, Fig. 1A) (31), confers a poor
TR 1-mediated transactivation as compared with TR 1. This poor
TR 1 activity correlates with its ability to efficiently bind the
MBPTRE as monomer. We thus further explored the
characteristics of the TR 1 monomer in terms of DNA sequence
requirements, functional properties, and co-factor interactions.
 |
MATERIALS AND METHODS |
Plasmids--
The construction of chloramphenicol
acetyltransferase (CAT) reporter genes, MBP( 256/+3)-CAT and
ME( 315/+3)-CAT, has been previously described (29, 33), and these
genes are here referred to as MBP 256 and ME 315, respectively. The
MBP/METRE and the MBP 256/5'm reporter gene were obtained
by PCR mutagenesis of the MBP 256 reporter according to the protocol
described for PCR technology (34). The following primers were
used for the MBP 256/5'm construct: MBP 187(+),
5'-AATGTTGAACGAGCTGAGGACACGGC-3'; MBP 176( ), 5'-AGCTCGTTCAACATTGTTCTGGATCGC-3'; MBP 260(+),
5'-GCTCTAGACTCTAGGCCTCGTACA-3'; MBP+9( ),
5'-CCGCTCGAGCGGATGGTCTGAAGCTCGT-3'. The following primers were used for
the MBP/METRE construct: p1,
5'-GGACGTTCGGGTTAGGGGAGGACACGGCGGTGACA-3'; p2,
5'-CCCTAACCCCAACGTCCTCTGGATCGCATCTGCCT-3'; p3,
5'-AACTGCAGGTCGACTCTAGAAGGCCTCGTACAGGC-3'; p4,
5'-AATGGCGAGGATCCCTCGAGTGAAGCTCGTCGGAC-3'.
MBPTRE/TATA and METRE/TATA reporter genes were
obtained by cloning the corresponding MBPTRE or
METRE double-stranded oligonucleotides upstream of the
33/+3 promoter sequence of the MBP gene, into the pBLCAT3 vector.
For the microinjection of Xenopus oocytes, the ME 315,
MBP 256, and MBP 256/5'm were subcloned into pBluescript for
single-stranded DNA preparations. The mycI(6-9)CAT plasmid was kindly
provided by Georges Spohr (35). For in vitro transcription,
the rat TR 1 and human RXR were subcloned into pSP64 (Promega).
The human RXR cDNA in which a Kozak sequence was introduced
(36), as well as the rat TR 1 and TR 1 cDNAs were subcloned
into pSG5PL (gift of Dr Hélène Richard-Foy (37)).
pCMV gal is from Amersham Pharmacia Biotech. A cDNA clone
encoding SRC-1 was kindly provided by Dr. Malcom Parker. Four regions
of this SRC-1 cDNA (A, nucleotide positions 67-617; B, 617-1259;
C, 1259-2330; and D, 2330-3391; numbering is according to the data
for GenBankTM accession no. U40396) were fused to
glutathione S-transferase (GST) into pGEX vectors (Amersham
Pharmacia Biotech). The N-CoR interaction domain (25) was cloned by
reverse transcription-PCR using mouse liver total RNA as template. The
cDNA obtained by reverse transcription using an oligo(dT) was
amplified by PCR with the EcoRI end primers N-CoR (+6715),
5'-GGAATTCCCTACTTGCCTTCATTCTTCAC-3', and N-CoR ( 7618),
5'-GGAATTCCCCATCATTTCTTCCTCATCCA-3' and was subcloned into the
EcoRI site of the pGEX2T vector (Amersham Pharmacia Biotech).
Transfections--
NIH3T3 cells were maintained in culture and
transiently transfected by electroporation as described previously
(32). Briefly, each cuvette contained 4 × 106 cells
at a density of 12.5 × 106 cells/ml and a total of 70 µg of plasmid DNA (30 µg of CAT reporter plasmid, 12 µg of each
expression vector (or as indicated in the figure legends), 1 µg of
pCMV gal as internal control for transfection efficiency, and pUC19
to complete to 70 µg of transfected DNA). After electroporation,
cells were distributed in four 60-mm dishes containing the transfection
medium supplemented with 100 nM T3 or with vehicle alone.
After 48 h, cell extracts were prepared and -galactosidase and
CAT activities were determined as described previously (32).
Electrophoretic Mobility Shift Assays--
Proteins for
electrophoretic mobility shift assays (EMSA) were obtained either by
in vitro transcription and translation using the rabbit
reticulocyte lysate system (Promega) or from Xenopus oocytes
whole cell extracts prepared as described below. RXR was prepared
from nuclear extract of Sf9 cells infected with a recombinant
baculovirus overexpressing mouse RXR as described (38). The fusion
proteins GST-N-CoR and GST-SRC were expressed in Escherichia
coli and purified as described by the manufacturer (pGEX vectors;
Amersham Pharmacia Biotech). The probes used correspond to the
double-stranded oligonucleotides indicated in the figures flanked on
their 5' side and 3' side by BamHI and HindIII
sequence, respectively, and labeled with
[ -32P]dATP.
For the binding reaction, the proteins were preincubated for 15 min at
room temperature, in a buffer containing 25 mM Hepes, pH
7.5, 5 mM MgCl2, 1 mM EDTA, 10%
glycerol, 40 mM KCl, 1 mM dithiothreitol, and 8 µg of salmon sperm DNA in a total volume of 20 µl. After a further
15-min incubation at room temperature in the presence of 30,000 cpm of
labeled probe, the complexes were separated on a 6% native
polyacrylamide gel. For DNA binding competition experiments, a
1.25-12.5-fold molar excess (as indicated) of the unlabeled double-stranded competitor oligonucleotide was added for further 10 min
after the incubation reaction. For kinetic experiments, a 50-fold molar
excess of unlabeled competitor oligonucleotide was added after the
incubation reaction and left for different time periods, as indicated
in the figures. Scanning and treatment of the autoradiographies were
performed using the Cirrus 1.2 software. When appropriate, gels were
analyzed by densitometry.
Microinjection of Xenopus Oocytes--
The preparation of
Xenopus stage VI oocytes and the microinjection procedure
were essentially as described in Wong et al. (39) using the
Nanoliter Injector (A203XVZ, World Precision Instruments, Inc.). The
rTR 1 (3 ng/oocyte) and human RXR (3 ng/oocyte) mRNAs were
injected into the cytoplasms of oocytes, which were incubated at
18 °C overnight in MBSH buffer (10 mM Hepes, pH 7.6, 88 mM NaCl, 1 mM KCl, 2.4 mM
NaHCO3, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM
Ca(NO3)2) supplemented with antibiotics (50 units/ml of ampicillin and streptomycin). Then the ME 315, MBP 256,
or MBP 256/5'm single-stranded reporter genes were microinjected into
oocyte nuclei (1 ng/oocyte) with the internal control mycI(6-9)CAT (0.2 ng/oocyte) as indicated in the legend of Fig. 6. The oocytes were
incubated in MBSH buffer supplemented with antibiotics during 6 h
and then collected for transcription analysis (see below). For EMSA, 10 oocytes were injected, and after an overnight incubation, whole cell
extracts were prepared as described previously (39).
Primer Extension Analysis--
A group of 15-20 oocytes was
collected per sample and homogenized in 10 µl/oocyte of 0.25 M Tris-HCl at pH 8.0. The equivalent of 10 oocytes was used
for RNA purification and transcription analysis. Total RNA was prepared
from the homogenate using the RNazolTM method (Tel-Test Inc.) as
described by Wong et al. (39). Half of the RNA sample (5 oocytes) was analyzed by primer extension.
The RNA (10 µl) was supplemented with 10 µl of a first strand
synthesis buffer (2×, provided by Life Technologies, Inc.), 5 mM dithiothreitol, and end-labeled CAT (5'-GGT GGT ATA TCC
AGT GAT TTT TTT CTC CAT-3') and H4 (5'-GGC TTG GTG ATG CCC TGG ATG TTA
TCC-3') primers (0.2 pmol each). The H4 primer, used as an internal
control, detects the endogenous histone H4 mRNA. Annealing occurred
for 10 min at 65 °C, 30 min at 55 °C, 20 min at 37 °C, and 5 min at room temperature. The reverse transcription reaction was carried
out at 42 °C upon the addition of 1 µl of 10 mM dNTPs and 100 units of the SuperscriptTMII RT (Life Technologies, Inc.). The
reaction was stopped after 1 h by ethanol precipitation. The extension products were resolved on a 8% sequencing gel, visualized by
autoradiography, and quantitated by densitometry. CAT mRNA levels
corresponding to ME 315, MBP 256, or MBP 256/5'm reporter were
standardized to the endogenous histone H4 mRNA levels.
 |
RESULTS |
The ME and MBP Genes Are Differentially Transactivated by TR 1
and TR 1--
To detect functional differences between the two main
TR subtypes in the regulation of the ME and MBP promoters, we used
transfection experiments in NIH3T3 cells. These cells express RXR as
most cell lines do but have very low TR mRNA levels (data not
shown). The two CAT reporter constructs used contain either the
promoter region of the ME gene up to 315 (ME 315), which encompasses
the TRE between 287 and 260 (32) or the MBP promoter up to position 256 (MBP 256) including the TRE located between positions 195 and
165 (31) (Fig. 1A). The
T3-mediated response of the ME 315 reporter gene increased with the
amounts of cotransfected expression plasmids for TR 1 or TR 1 (Fig.
1B). However, repression by the unliganded TR 1 (mean
value of 58% of repression when the cells were transfected with 3 µg
of expression plasmid, p < 0.05) was more important
than in the presence of TR 1 (mean value of 73% for the
corresponding point, statistically not significant). The overall
T3-induced response was also more potent with TR 1 than with TR 1,
a difference that cannot be attributed to TR 1 and TR 1 differences
in expression levels (see below). As seen in Fig. 1C, the
MBP 256 reporter gene poorly responded to T3 and TR 1, and this
response was not improved by transfection of higher amounts of TR
expression vector. In contrast, TR 1-mediated activity was
dose-dependent, leading to a significant difference in T3 response between the two TR subtypes. Because of the opposite results
obtained when using the ME and the MBP reporter genes, we can rule out
an apparent functional difference that would be due to a difference in
the level of receptor expression. This was further assessed by a RNase
protection assay that showed that the level of TR 1 and TR 1
mRNA after transfection were similar (data not shown). Moreover,
the same pattern of activation and repression was observed using
different vectors for expressing TRs (pRSV instead of pSG5PL; data not
shown). Thus, in transfected NIH3T3 cells, TR 1 induces a strong T3
response of ME 315 but a weak activation of MBP 256. In contrast,
TR 1 mediates an efficient T3 stimulation of both ME and MBP reporter
genes.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
Differential transactivation properties of
TRs. A, schematic representation of the CAT reporter genes.
The respective positions and sequences of the METRE,
organized as a direct repeat (DR4), and MBPTRE, organized
as an inverted palindrome (IP6), are given within their wild type
promoter context (ME 315, MBP 256). B, comparison of the
T3 response mediated by TR 1 (filled bars) and TR 1
(striped bars) using the ME 315 reporter construct. NIH3T3
cells were cotransfected with the reporter construct (7.5 µg/dish)
and increasing amounts of pSG5TR 1 or pSG5TR 1 in the presence (+)
or absence ( ) of 100 nM T3 as indicated. The total amount
of expression plasmid was adjusted to 3 µg with the empty vector
pSG5. A pCMV (0.25 µg/dish) was included as an internal control.
CAT activity levels were standardized to -galactosidase expression.
The basal activity of the reporter plasmid in the absence of receptor
and T3 was set to 1. Results are the mean ± S.E. of at least
three independent experiments. Statistical analyses show that the
repression by the unliganded TR 1 is significant (Student's
t test value, p = 0.02) in contrast to that
mediated by TR 1. The overall difference of the T3 response mediated
by TR 1 and TR 1 is also significant (p < 0.05).
C, comparison of the T3 response mediated by
TR 1 (filled bars) and TR 1 (stripped bars)
using MBP 256. The experimental conditions used are as described in
B. The difference in the T3 response mediated by TR 1 and
TR 1 is significant at 1.5 and 3 µg of expression plasmid
(Student's t test value, p < 0.01).
D, effect of the TRE structure in the T3 response mediated
by TRs. Transfection in NIH3T3 cells of MBP 256 or
MBP/METRE CAT reporter genes with pSG5, pSG5TR 1, and
pSG5TR 1 (3 µg/dish), as described for B is shown. Both
MBPTRE/TATA and METRE/TATA CAT reporter genes
were cotransfected in NIH3T3 cells with pSG5 or pSG5TR 1 (3 µg/dish).
|
|
Role of the TRE Structure in the Transactivation Potency of TR 1
and TR 1--
One distinct feature of the ME and MBP promoter that
may participate in their different patterns of regulation by T3
concerns the TRE structure, which corresponds to a DR4 in the ME
promoter and to an inverted palindrome with a 6-base pair spacing (IP6) in the MBP promoter (Fig. 1A). To evaluate whether the
nature of the TRE was responsible of the poor TR 1-mediated T3
responsiveness of the MBP promoter, we changed the MBPTRE
for METRE within the context of the MBP promoter
(MBP/METRE; Fig. 1A). As seen in Fig. 1D, TR 1 mediated a similar T3 responsiveness of the wild
type and mutated promoter, in contrast to TR 1, which was
significantly more efficient when the METRE replaces the
MBPTRE. A distinct role of these two TREs in the potency of
TR 1-mediated transcriptional activation was further analyzed in the
context of a common minimal promoter that only contains the TATA region
from 33 to +3 of the MBP promoter (MBPTRE/TATA and
METRE/TATA). In this context again, the MBPTRE
solely conveyed a low activation by TR 1 as compared with that
mediated by METRE (5-fold versus 15-fold,
respectively). We thus can conclude that in these different promoter
contexts, the MBPTRE element is by itself responsible of
the poor TR 1-mediated response of the MBP promoter, while it
mediates efficient regulation by TR 1.
Binding Pattern of TR 1 and TR 1 on METRE and
MBPTRE--
To evaluate whether the specific pattern of T3
response through particular response elements by TR 1 may reflect
differences in DNA binding properties of the TR subtypes, EMSAs were
performed with labeled double-stranded oligonucleotides corresponding
to the two TREs. Neither TR 1 nor TR 1 was able to bind to the ME probe in absence of RXR. The addition of RXR to the TRs resulted in the
formation of a major complex that corresponds to the TR/RXR heterodimer
(Fig. 2A). The absence or
presence of T3 in the reaction did not change the strength of this
signal (data not shown). Binding of TRs to the MBPTRE was
quite different from this pattern. In absence of RXR, TR 1 formed two
complexes: a fast migrating complex that corresponds to a TR 1
monomer and a slower complex corresponding to a TR 1 homodimer (Fig.
2B). The addition of T3 triggered the disappearance of the
upper complex (Fig. 2B, compare lanes
3 and 4) while provoking a small but reproducible
downshift of the faster migrating complex, consistent with their
identification as TR homodimer and monomer, respectively (22-24).
Increasing amounts of TR 1 resulted in a parallel increase of the
intensity of both the monomer and the homodimer bands (Fig.
2B, lanes 7-9), indicating the
absence of cooperativity for the formation of the homodimer. In the
presence of both TR 1 and RXR, a third complex was detected. This
complex corresponds to a TR 1/RXR heterodimer and was not disrupted
by T3 (Fig. 2B, lanes 5 and
6). As seen in Fig. 2C, TR 1 was also able to
form a retarded complex on the MBPTRE in absence of RXR.
Its slow migration and T3-induced disruption identified it as a TR 1
homodimer (Fig. 2C, lanes 1 and
2). No complex corresponding to a TR 1 monomer was
observed (Fig. 2C, lanes 5-7),
although trace amounts were occasionally detected in presence of high
concentrations of TR 1. In the presence of RXR, TR 1/RXR
heterodimers were formed and showed a slightly increased mobility in
presence of T3 (Fig. 2C, lanes 3 and
4). The addition of more RXR to TR 1 or TR 1-containing binding reactions with the MBPTRE probe resulted in the
exclusive detection of TR 1/RXR or TR 1/RXR complexes (data not
shown). In summary, TR 1/RXR and TR 1/RXR complexes form with a
similar efficiency on both TREs. However, a striking difference resides in the binding of TR 1 monomers and TR 1 homodimers to the
MBPTRE, whereas such complexes are not seen on the
METRE.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2.
Distinct in vitro binding pattern
of TRs to the METRE and MBPTRE. EMSAs
using in vitro translated TR 1 or TR 1 in the presence
or absence of Sf9-expressed recombinant RXR and of 100 nM T3 as indicated were incubated with a radiolabeled
oligonucleotide encompassing the METRE sequence
(A) or the MBPTRE sequence (B and
C). In B, lanes 7-9, increasing
amounts of in vitro translated TR 1 (6, 15, and 30 fmol,
respectively) show the noncooperative binding of TR 1 monomers in the
absence of RXR. In C, lanes 5-7, increasing
amounts of in vitro translated TR 1 (6, 15, and 30 fmol,
respectively) do not allow the detection of TR 1 monomer. In all
panels, TR indicates the monomer complex,
TR/TR indicates the homodimer complex, and TR/RXR
indicates the heterodimer complex.
|
|
We further characterized the properties of the TR 1-containing
complexes bound to MBPTRE by competition experiments in
EMSA. In such experiments, unlabeled DNA response elements compete with the labeled probe for TR binding, allowing the measurement of either
the affinity or the off-rate of the TR 1/MBPTRE complex depending on the experimental design. At equilibrium, a 4-fold molar
excess of cold competitor led to a 50% decrease in hetero- and
homodimer complexes, while more than 10-fold molar excess was required
for a similar inhibition of the monomer complex (Fig. 3A). This result indicates
that the affinity of TR 1 monomer binding is lower than that of dimer
binding. A kinetic study showed the disappearance of the complexes as a
function of time in presence of a 50-fold molar excess of the
competitor. Most of the monomer and most of the homodimer complexes
disappeared within the first minute, while 3 min were needed to reduce
the heterodimer complex to only 50% (Fig. 3B). This result
suggests that the off-rate of TR 1 monomer and homodimer from
MBPTRE is higher than that of the TR 1/RXR
heterodimer.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Competition and kinetic DNA binding studies
of TR 1 monomers, homodimers, and heterodimers. EMSAs using
in vitro translated TR 1 incubated with the radiolabeled
MBPTRE probe were performed in the presence of
Sf9-expressed recombinant RXR so that the three complexes
(monomer, homodimer, and heterodimer) could be observed. A,
after 15 min of incubation, competitions were performed during 10 min
in the absence of or with a 1.25-, 2.5-, 5-, and 12.5-fold molar excess
of unlabeled MBPTRE (lanes 1-5, respectively).
B, after 15 min of incubation, a 50-fold molar excess of
unlabeled MBPTRE was added to the reaction, which was
stopped after 0, 1, 3, 5, and 10 min (lanes 1-5,
respectively). The graphs on the left correspond
to the densitometric analysis of the autoradiographs shown on the
right.
|
|
Binding of TR 1 as Monomer Requires a Specific Extended
Half-site--
The occurrence of a high monomer binding efficiency
that was TRE and TR subtype-specific prompted us to identify the
corresponding sequence requirement present in MBPTRE.
Mutation of the downstream half-site with respect to the orientation of
the TRE in the wild-type promoter (MBP 3'm; Fig.
4A) completely abolished
TR 1 as well as TR 1 binding in the absence and in the presence of
RXR (Fig. 4B, lanes 5-8). In
contrast, mutation of the 5' half-site (MBP 5'm; Fig. 4A)
did not affect TR 1 monomer binding, but neither TR 1 nor TR 1
homodimers could form (Fig. 4B, lanes
9 and 11). These results further excluded the
possibility that the complex migrating as homodimer corresponds to the
independent and adjacent binding of two TR molecules. However, most
unexpectedly, TR 1/RXR and TR 1/RXR did bind to MBP 5'm although to
a lesser extent than to the wild type MBPTRE (Fig.
4B, compare lanes 10 and 12 with lanes 2 and 4). The same results
were obtained when the mutation introduced in the 5' half-site
consisted of random nucleotides (Fig. 4B, compare MBP 5'm
lanes 9-12 with MBP 5'm/N lanes
13-16). This ruled out a possible artifact due to the
nature of the mutations and clearly demonstrated that the TR 1
monomer specifically binds to the 3' half-site. The importance of the
three nucleotides flanking the AGGACA core hexamer of this half-site in
5' was then assessed by mutating them within the full-length
MBPTRE (MBP agt, Fig. 4A). These mutations
abolished detectable monomer binding and thus demonstrated that the
nonanucleotide CTGAGGACA is required in the wild-type
MBPTRE for TR 1 monomer binding (Fig. 4B,
lanes 17-20). Moreover, the formation of TR/RXR
heterodimer complexes onto MBP agt dramatically decreased, indicating
that heterodimers also make specific contacts with these nucleotides.
In summary, these mutagenesis experiments demonstrated that (i) only
the 3' extended half-site of MBPTRE is capable of binding
the TR 1 monomer and (ii) this specific half-site also strongly
participates in the binding of TR/RXR heterodimer.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 4.
Specific binding of TRs on the 3' half-site
of MBPTRE. A, sequences of wild type and
mutated MBPTRE. The arrows underline
hexameric half-sites, and regions enclosed in shaded
boxes correspond to mutated sequences. B, EMSAs
using in vitro translated TR 1 and TR 1 incubated in the
presence or absence of Sf9-expressed recombinant RXR, as
indicated. The radiolabeled probes are as indicated below
each panel. For comparison, lanes 1-4
correspond to the observed complexes bound onto the wild type TRE, run
with the same extracts and on the same gel as lanes
9-12. In lanes 2 and 4,
heterodimers appear as a doublet, whose fainter and faster migrating
complex is composed of TR and a protein from Sf9 extract, most
likely USP (72).
|
|
Analyses of the Transcriptional Activity of TR 1 Monomer--
In
a first set of experiments, we introduced the mutation corresponding to
MBP 5'm into the wild-type MBP promoter, creating MBP 256/5'm, and
used this reporter gene in transfection assay of NIH3T3 cells. This
reporter gene bearing only a half-site TRE exhibited a weak but
significant response to T3 (Fig. 5). The T3 response by both TR 1 and TR 1 was affected by the mutations and
corresponded to the reduction of the efficiency of the TR/RXR heterodimer binding onto MBP 5'm (see Fig. 4B). Thus, the
correlation between the intensity of heterodimer binding and the
transactivation level suggested that, in transfected cells, the binding
of heterodimers onto the half-site rather than the monomer formation,
which was not affected by the mutation, may account for the residual
response.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Functional analyses of the TR 1 monomer
binding site. NIH3T3 cells were cotransfected with the wild type
MBP 256 or with the mutation MBP 256/5'm reporter plasmid. pSG5,
pSG5TR 1, and pSG5TR 1 (3 µg/dish) were cotransfected in the
presence or absence of 100 nM T3 as indicated. pCMV
(0.25 µg/dish) was included as an internal control. CAT activity
levels were standardized to -galactosidase expression. The basal
activity of the reporter plasmid in the absence of receptor and T3 was
set to 1. Results are the mean ± S.E. of three independent
experiments.
|
|
To assess the respective roles of TR 1 monomer and TR 1/RXR
heterodimer in TR 1-mediated T3 response, we analyzed the
transactivation properties of TR 1 and TR 1 in Xenopus
oocytes, since they do not express detectable amounts of TR and RXR
proteins (39). Oocytes from stages VI were injected with TR mRNA
alone or with RXR mRNA. The corresponding oocyte extracts were then
used in an EMSA, yielding similar binding patterns as those observed
with TR expressed in reticulocyte lysate. As expected, when using the MBPTRE as probe, TR 1 formed mainly monomer and TR 1
homodimer, whereas heterodimer formation was only seen upon coinjection
of RXR mRNA (Fig. 6A).
Surprisingly in this model, unliganded TR 1 or TR 1 in absence of
RXR mediates a strong repression of MBP 256 reporter gene as measured
by primer extension of the RNA transcripts. The addition of T3 relieved
this repression and further enhanced the CAT gene expression above the
basal level. This T3 effect was slightly reinforced upon co-injection
of RXR mRNA (Fig. 6B and 6B'). The same
pattern of regulation was observed when using the MBP 256/5'm vector,
to which TR 1 monomer binds efficiently, whereas TR/RXR binds with a
lower affinity (see Figs. 4B and 6C). The fact
that TR 1 cannot bind to MBP 256 as a monomer nor to MBP 256/5'm as
a homodimer suggested that neither of these complexes could explain the
TR activity in the absence of RXR. We thus further analyzed the
regulation of the ME reporter gene onto which only heterodimer could be
observed. Again, unliganded TR 1 and TR 1 in the absence of RXR
caused a repression, while the addition of T3 to these oocytes led to
an activation of the ME reporter gene. Further addition of RXR improved
the T3-mediated induction (Fig. 6D). The reporter
mycI(6-9)CAT vector used as a control was not responsive to the
presence or the absence of receptors and/or T3 (data not shown).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 6.
TR 1 and TR 1 expressed in Xenopus
oocytes mediates a T3 response. A, in vitro
transcribed mRNAs (lanes 1-12) corresponding to TR 1
or TR 1 and/or human RXR were injected into Xenopus
oocyte cytoplasm (mRNA). Whole cell extracts were prepared as
described under "Materials and Methods" and analyzed by EMSA with
the radiolabeled MBPTRE probe (lanes 1-6) and
the MBP5'm probe (lanes 7-12). B, B',
C, and D, Xenopus oocytes were
microinjected into the cytoplasm with TR 1 mRNA (3 ng/oocyte),
TR 1 mRNA (3 ng/oocyte), with or without RXR mRNA (3 ng/oocyte) as indicated at the top of each panel.
After an overnight incubation, nuclei were microinjected with MBP 256
(B, B'), MBP 256/5'm (C), or ME 315
(D) CAT reporter genes (1 ng of single-stranded DNA/oocyte).
Oocytes were further incubated 24 h in the presence (+) or absence
( ) of 100 nM T3. Primer extension analyses of total RNA
from 10 oocytes/sample were performed with a radiolabeled CAT primer
for the reporter gene activities together with the H4 primer as
internal control.
|
|
Thus, in the mammalian NIH3T3 cells, a correlation could be made
between the low efficiency of TR binding as a heterodimer on an
extended half-site TRE and the weak T3 response it mediates. However, a
transcriptional activity of the DNA-bound TR 1 monomer in mammalian
cells could not be completely excluded based on these experiments. In
contrast, in Xenopus oocytes, TR 1 and TR 1 can repress
reporter gene expression in the absence of T3 and induce it in the
presence of T3, regardless of whether RXR mRNA is co-injected. These activities do not correlate with the ability to form monomer or
homodimer, raising the hypothesis that some Xenopus
oocyte-specific nuclear factors are participating as partners of TR 1
and TR 1 in this experimental model.
The TR 1 Monomer Interacts Neither with N-CoR Nor with
SRC-1--
The interaction of TR with co-repressors such as N-CoR or
SMRT was shown to participate in the transcriptional repression mediated by TR in the absence of its ligand (25, 26), while the
co-activator SRC-1 plays a role in the positive enhancement of gene
expression mediated by liganded TR (27). Both factors are present in
NIH3T3 cells and thus should be involved in TR 1 monomer activity, if
there is any. Using EMSAs, we thus assessed the specific interacting
properties of DNA-bound TR 1 complexes with these co-factors. Because
the high molecular weight of N-CoR and SRC-1 precluded their use as
full-length proteins in EMSA, we expressed the mouse N-CoR domain known
to interact with nuclear receptors (25) as a GST fusion protein (Fig.
7A). Interestingly, as shown
in Fig. 7, TR 1 bound as a monomer on MBPTRE as well as
on MBP 5'm was not able to bind N-CoR, since no supershift was observed
(Fig. 7B, lanes 1-7). In contrast, the DNA-bound TR/RXR heterodimer was supershifted in the presence of N-CoR, due to
the formation of a ternary complex. T3 addition led to the disruption
of this higher order complex and to the reappearance of the heterodimer
(Fig. 7B, lanes 8-10).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 7.
TR 1 monomer bound to MBPTRE
does not interact with N-CoR. A, schematic representation of
the murine N-CoR cDNA. Two amino-terminal repressing domains (RDI,
nucleotides 117-1053; RDII, nucleotides 2373-3165) are represented by
shaded boxes, and the C-terminal interacting
domain is shown by a black box (ID,
nucleotides 6834-7017). The N-CoR region from nucleotide 6715 to 7618, encompassing the interaction domain with TR, was subcloned into the
pGEX2T vector. The GST fusion protein was expressed in E. coli and used in EMSA. B, EMSAs using in
vitro translated TR 1 incubated in the presence or absence of
GST-N-CoR (1 µg of partially purified protein), 100 nM
T3, and Sf9-expressed recombinant RXR as indicated. The
radiolabeled probe was MBPTRE (lanes 1-3 and
8-10) or MBP 5'm (lanes 4-7). A specific
interaction of DNA-bound TR/RXR with N-CoR is released by T3, which
also provoked a small downshift of the TR/RXR complex.
|
|
To analyze the interaction of SRC-1 with TR complexes bound to DNA, we
first subcloned consecutive regions (arbitrarily called A, B, C, and D)
of the SRC-1 cDNA into an expression vector. We then tested the
different domains for their interaction with the TR 1/RXR heterodimer
(see Fig. 8A). The region B
from amino acid 188 to 401, according to the human SRC-1 sequence (27),
showed a T3-dependent interaction with the DNA-bound
heterodimer, while the three other regions, A, C, and D, did not (Fig.
8B, lanes 1-5 and data not shown).
Interestingly, the monomer bound to MBPTRE or MBP 5'm was
unable to form a complex with the SRC-1 B region in the absence or
presence of T3 (Fig. 8B, lanes 6-10).
The small reduction in the monomer band intensity in presence of T3
might reflect the TR 1/SRC-1 interaction occurring in solution.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 8.
TR 1 monomer bound to MBPTRE
does not interact with SRC-1. A, schematic representation of
the SRC-1 cDNA. The different regions of the SRC-1 cDNA
(A, nucleotides 67-617; B, nucleotides
617-1259; C, nucleotides 1259-2330; D,
nucleotides 2330-3391) were subcloned into the pGEX 5 × 3 vector. The GST fusion proteins were expressed in E. coli
and used in EMSA. B, EMSAs using in vitro
translated TR 1 incubated in the presence or absence of GST-SRC-1
clone A or clone B (1 µg of partially purified protein) in the
presence or absence of 100 nM T3 and RXR, as indicated. The
radiolabeled probes were MBPTRE (lanes
1-8) or MBP 5'm (lanes 9-10).
|
|
In summary, while the TR interactions with co-factors in solution are
well documented, we demonstrated herein that the DNA-bound TR 1
monomer is unable to interact either with N-CoR or with SRC-1, thereby
providing a molecular explanation for the weak, if existent, transcriptional regulatory properties (repression or activation) of the
TR 1 monomer in mammalian cells.
 |
DISCUSSION |
In this study, we report on the differential regulation of the MBP
promoter by TR 1 and TR 1 in mammalian cells. We show that the
weakness of the T3 response mediated by TR 1 correlates with its
ability to form monomers on the MBPTRE. This TR 1 monomer interacts neither with the N-CoR nor with the SRC-1 domains known to
interact with the receptor. These functional characteristics may have
profound implications with respect to the T3 regulation of the MBP gene
during development.
Binding of TR Monomer Has Specific Sequence
Requirements--
Binding of TR as a monomer was first described using
the synthetic TREpal as probe (40). Later, the observation that
nucleotides flanking the core hexamer might affect TRE activity (41)
was at the basis of an unbiased search for an optimal DNA binding sequence for TR 1 monomer, which resulted in the octameric sequence 5'-TAAGGTCA (42). Further work with diverse synthetic octameric sequences determined the 5'-(T/C)(A/G)AGGTCA-3' motif as consensus half-site for the TR 1 monomer (43). Among the natural elements, the
rat growth hormone, the chick lysozyme, and the rat - and -myosin
heavy chain genes also contain positive TREs comprising an optimal or
suboptimal octamer sequence to which TR binds as monomer (23, 44-49).
In the natural elements that we analyzed, the MBPTRE
sequence contains the nonamer CTGAGGACA whose disruption in the 5' part
or in the core sequence results in the loss of TR 1 monomer binding
(see Fig. 4B). In contrast, the sequence of the two
half-sites that composes the METRE and taken as nonamers are TTGGGGTTA and GGGAGGACA. None of them can bind TR 1 monomer in
the conditions used in the present work, indicating that TR 1 monomer
binding has strict requirements covering at least 8 or 9 nucleotides.
Some reports, however, indicated that purified E. coli-expressed TR may bind as a monomer to METRE (44,
45, 48). Two nonexclusive hypotheses can explain the apparent
discrepancies with our own work. First, the amount of TR expressed in
E. coli may be much higher than that obtained in
reticulocyte lysate, allowing the detection of low affinity complexes.
Second, post-translational modifications that do not occur in E. coli could be important for TR binding properties (50) as shown
for c-erbA 2, which binds as monomer only after mutation
of two phosphorylation sites (51).
TR/RXR Can Bind an Extended Half-site--
Surprisingly, the
nonamer present in the MBPTRE, to which TR 1 monomer
binds, also allowed the formation of TR/RXR heterodimer but not of
TR/TR homodimer complexes (see Fig. 4B). This suggests that,
since TR and RXR heterodimerize in solution (13), the strong and
specific anchorage of TR onto its half-site allows weaker or
nonspecific DNA contacts by RXR. This is indeed substantiated by
methylation interference assays, which showed that RXR contacts the 5'
half-site of a DR4 with rather weak bonds, as compared with those of TR
with the 3' half-site (52, 53). This ability of a heterodimer to bind
to an extended half-site may also explain some unexpected observations
of TR/RXR binding to direct repeats elements with a variety of spacing
lengths between the half-sites (54, 55). This is reminiscent of the
RXR/Nurr1 heterodimer, which can trigger a 9-cis-retinoic
acid responsiveness through an 8-base pair monovalent site (56).
Activation by TR through an octamer element has been previously
reported and was attributed to the monomer activity (57). Herein, we
demonstrated that TR/RXR heterodimers are probably responsible for the
extended half-site activity that we detected.
DNA-bound TR Monomer Does Not Interact with NCoR or
SRC-1--
Recent studies on the mechanism of action of nuclear
receptors identified factors with which they interact (58). More
precisely, two co-repressors N-CoR and SMRT interact with the
unliganded TR, while TR interaction with the co-activators SRC-1 and
p300/CBP is T3-dependent (25, 26, 28, 59, 60). These
interactions were characterized using yeast two-hybrid systems or
pull-down assays and showed that TR or TR/RXR interacted with these
co-factors in solution. Herein, we demonstrated by EMSA that TR monomer
bound to MBPTRE interacts neither with GST-N-CoR nor with
GST-SRC-1. The DNA-bound heterodimer, in contrast, forms a ternary
complex with N-CoR in the absence of T3 (herein and Ref. 25) and
interacts with SRC-1 in presence of T3. While this manuscript was in
preparation, Zamir et al. (61) also showed that DNA-bound TR
monomer does not interact with GST-NCoR.
Two distinct domains of TR mediate the interaction with these two
co-factors. N-CoR interacts with the hinge region of TR (62, 63), while
a mutation in the helix 3 or in the helix 12 of the ligand binding
domain impaired the interaction with SRC-1 (64, 65). Whether the TR
molecule is in solution or bound to DNA as a monomer may modify the
accessibility of these interacting domains. Since SRC-1 can contact
both TR and RXR, it is also possible that a co-activator may need to be
in contact with two molecules in order to stabilize the interaction.
Alternatively, RXR may induce a conformational transition on TR,
affecting its interaction with SRC-1. In any case, the absence of
interaction of the TR 1 monomer with the co-factors tested provides a
mechanistic explanation for the lack of TR 1 monomer transcriptional
activity.
Functional and Structural Differences of TR 1 and TR 1--
So
far, all T3-responsive genes analyzed in transfections exhibit an equal
or slightly better responsiveness to TR 1 than to TR 1 as
emphasized herein with the ME gene. Besides a T3-independent TR 1-specific activation of the pcp-2 gene (66), the MBP
promoter is the first example of a clear contrast between TR 1- and
TR 1-mediated T3 responsiveness. In parallel, previous EMSAs
performed on various synthetic and natural elements indicated that
TR 1 more readily homodimerizes than TR 1 and that TR 1 binds
more easily as monomer than TR 1 (23, 40, 44, 46, 67). In this
respect, the binding pattern of TR 1 and TR 1 to the
MBPTRE is paradigmatic.
The ability of binding as a monomer is mostly a property of orphan
nuclear receptors (19), and the structural determinants involved in
monomer binding were particularly well analyzed for the orphan receptor
NGFI-B. Binding of NGFI-B to an extended half-site involves the A and T
boxes of the receptor, located in the hinge region (68). In TR, a long
-helix in this region that interacts with the minor groove of the
half-site and with its flanking sequence (69) may participate in DNA
contacts required for binding of TR as monomer. Little difference in
the A and T boxes is seen between TR 1 and TR 1. However, the
C-terminal part of the hinge domain is more divergent and may play a
role in the differences seen in binding patterns. In parallel,
dimerization determinants are found in the TR ligand binding domain as
well as in the DNA binding domain (10). Detailed comparative analyses
of the structural differences within these domains in TR 1 and
TR 1, using the MBPTRE as the DNA partner would help to
precisely identify the TR determinants for monomer and homodimer
formation. They may also give a tool for understanding the homodimer
function, which remains elusive.
Transcriptional Regulatory Patterns Mediated by TR Differ in NIH3T3
Cells and in Xenopus Oocytes--
Xenopus oocytes provide a
model in which RXR has not been detected (39). The results we obtained
in this model are surprising. First, without co-injecting RXR mRNA
and in the absence of T3, both TR isotypes led to a strong repression
of reporter genes carrying various TREs: an IP6, a half-site, or a DR4.
That a TR monomer could be responsible for such an activity was not
supported by the fact that TR 1 onto MBPTRE and TR 1 or
TR 1 onto the METRE could not form monomer. The same
reasoning applies to the involvement of homodimers that were
exclusively seen with the MBP 256. Second, in this model, no
differences between TR 1 and TR 1 were observed. One hypothesis
would be that, in oocytes, TR irrespective of the complex that it forms
on DNA is able to recruit partners possibly different from those known
in mammalian cells. They are unlikely to be RXR homologues, since no
RXR-like activity was detected in the oocyte extracts obtained after TR
mRNA injection (Fig. 6A; see also Ref. 39). Little is
known yet about the co-repressors and co-activators that are present in
Xenopus oocytes. Their analysis could be highly valuable to
understand the TR mechanism of action in these cells.
TR 1 and TR 1 in the Regulation of the MBP Gene during Brain
Development--
In rat embryos from E14 onwards, TR 1 mRNA is
detectable at high levels during all developmental stages of the brain,
whereas TR 1 mRNA is low or undetectable. The insensitivity of
MBP to T3 regulation at that time suggests that TR 1 may indeed
occupy the MBPTRE sequence as monomer during development.
After birth, TR 1 mRNA expression peaks during the first 3 weeks
(2, 7, 8). This correlates with high myelinating activity and high T3-dependent MBP expression. Our experiments suggest that
after birth, the nonproductive promoter occupancy by TR 1 monomer is challenged by the rise in TR 1 concentration. In this model, the relative intracellular concentration of TR and RXR is an important determinant of the hormonal response as kinetic studies emphasize the
higher affinity and better stability of the TR/RXR heterodimer complex
versus homodimer and monomer (herein and Refs. 40 and 54).
Three RXR isotypes are expressed in mammals, and all are able to form
heterodimers with TR (18). RXR and RXR transcripts have been
detected by in situ hybridization in the central nervous system of the mouse embryo from day 10.5 onwards and in the adult (18,
70). Thus, both TRs and RXRs are present during the myelination period;
however, their relative levels are not known. It must also be kept in
mind that the interaction of TRs with the MBPTRE in neural
tissue may involve other tissue-specific factors in addition to RXR,
which might result in a transactivation pattern different from that we
have observed in NIH3T3 cells. In view of the rather high level of
TR 1 expression in the developing brain, associated with the high
efficiency with which TR 1 monomers bind to the MBPTRE,
the physiological relevance of TR 1 monomers deserves further
consideration.
In conclusion, our results reveal a new TR mode of action, which is
specific to TR 1 monomers, which bind to a monovalent site present in
otherwise functional TREs. This pathway may play an important role in
modulating T3 effects at different stages of development when TR 1
and RXR expression varies. At the molecular level, this study first
emphasizes the stringent DNA sequence requirement for TR 1 monomer
binding in vitro. It also stresses the importance of
carefully assessing the interaction of co-factor/receptor in the
context of DNA-bound complexes, which may differ from interactions in
solution. Altogether, our results strengthen the hypothesis that DNA,
i.e. the TREs herein, exert an allosteric control of the
transcriptional activities of nuclear receptors (71).
 |
ACKNOWLEDGEMENTS |
We thank W. Wahli for helpful discussions
during the preparation of the manuscript and O. Hagenbüchle and
N. Mermod for reading it critically. We also thank M. Parker, H. Richard-Foy, and A. Hihi for the gift of SRC-1, pSG5-PL, and
RXR-containing Sf9 cellular extracts, respectively, and J. Goudet for statistical analyses.
 |
FOOTNOTES |
*
This work was supported by the Etat de Vaud and the Swiss
National Science Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Institut de Biologie
Animale Bâtiment de Biologie, Université de Lausanne
CH-1015 Lausanne, Switzerland. Tel.: 41 21 692 41 40; Fax: 41 21 692 41 15; E-mail: beatrice.desvergne{at}iba.unil.ch.
The abbreviations used are:
TR, thyroid hormone
receptor; TRE, thyroid hormone response element; T3, thyroid hormone; ME, malic enzyme; MBP, myelin basic protein; DR, direct repeat; IP, inverted palindrome; RXR, 9-cis-retinoic acid receptorCAT, chloramphenicol acetyltransferaseGST, glutathione
S-transferaseEMSA, electrophoretic mobility shift
assay.
 |
REFERENCES |
-
Gronemeyer, H.,
and Laudet, V.
(1995)
Protein Profile
2,
1173-1308[Medline]
[Order article via Infotrieve]
-
Strait, K. A.,
Schwartz, H. L.,
Perez-Castillo, A.,
and Oppenheimer, J. H.
(1990)
J. Biol. Chem.
265,
10514-10521[Abstract/Free Full Text]
-
Forrest, D.,
Sjöberg, M.,
and Vennström, B.
(1990)
EMBO J.
9,
1519-1528[Medline]
[Order article via Infotrieve]
-
Bradley, D. J.,
Young, W. S., III,
and Weinberger, C.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
7250-7254[Abstract/Free Full Text]
-
Strait, K. A.,
Schwartz, H. L.,
Seybold, V. S.,
Ling, N. C.,
and Oppenheimer, J. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3887-3891[Abstract/Free Full Text]
-
Forrest, D.,
Hallbook, F.,
Persson, H.,
and Vennström, B.
(1991)
EMBO J.
10,
269-275[Medline]
[Order article via Infotrieve]
-
Mellström, B.,
Naranjo, J. R.,
Santos, A.,
Gonzalez, A. M.,
and Bernal, J.
(1991)
Mol. Endocrinol.
5,
1339-1350[Abstract/Free Full Text]
-
Bradley, D. J.,
Towle, H. C.,
and Young, I. W. S.
(1992)
J. Neurosci.
12,
2288-2302[Abstract]
-
Bradley, D. J.,
Towle, H. C.,
and Young, W. S.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
439-443[Abstract/Free Full Text]
-
Desvergne, B.
(1994)
Mol. Cell. Endocrinol.
100,
125-131[CrossRef][Medline]
[Order article via Infotrieve]
-
Yu, V. C.,
Delsert, C.,
Andersen, B.,
Holloway, J. M.,
Devary, O. V.,
Naar, A. M.,
Kim, S. Y.,
Boutin, J. M.,
Glass, C. K.,
and Rosenfeld, M. G.
(1991)
Cell
67,
1251-1266[CrossRef][Medline]
[Order article via Infotrieve]
-
Leid, M.,
Kastner, P.,
Lyons, R.,
Nakshatri, H.,
Saunders, M.,
Zacharewski, T.,
Chen, J. Y.,
Staub, A.,
Garnier, J. M.,
Mader, S.,
and Chambon, P.
(1992)
Cell
66,
377-395
-
Marks, M. S.,
Hallenbeck, P. L.,
Nagata, T.,
Segars, J. H.,
Appella, E.,
Nikodem, V. M.,
and Ozato, K.
(1992)
EMBO J.
11,
1419-1435[Medline]
[Order article via Infotrieve]
-
Kliewer, S. A.,
Umesono, K.,
Mangelsdorf, D. J.,
and Evans, R. M.
(1992)
Nature
355,
446-449[CrossRef][Medline]
[Order article via Infotrieve]
-
Zhang, X. K.,
Hoffman, B.,
Tran, P.-B. V.,
Graupner, G.,
and Pfahl, M.
(1992)
Nature
355,
442-446
-
Bugge, T. H.,
Pohl, J.,
Lonnoy, O.,
and Stunnenberg, H. G.
(1992)
EMBO J.
11,
1409-1418[Medline]
[Order article via Infotrieve]
-
Sugawara, A.,
Yen, P. M.,
Darling, D. S.,
and Chin, W. W.
(1993)
Endocrinology
133,
965-971[Abstract/Free Full Text]
-
Mangelsdorf, D. J.,
Borgmeyer, U.,
Heyman, R. A.,
Zhou, J. Y.,
Ong, E. S.,
Oro, A. E.,
Kakizuka, A.,
and Evans, R. M.
(1992)
Genes Dev.
6,
329-344[Abstract/Free Full Text]
-
Mangelsdorf, D.,
and Evans, R.
(1995)
Cell
83,
841-850[CrossRef][Medline]
[Order article via Infotrieve]
-
Hsu, J.-H.,
Zavacki, A.,
Harney, J.,
and Brent, G.
(1995)
Endocrinology
136,
421-430[Abstract]
-
Lee, I. J.,
Driggers, P. H.,
Medin, J. A.,
Nikodem, V. M.,
and Ozato, K.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1647-1651[Abstract/Free Full Text]
-
Andersson, M. L.,
Nordström, K.,
Demczuk, S.,
Harbers, M.,
and Vennström, B.
(1992)
Nucleic Acids Res.
20,
4803-4810[Abstract/Free Full Text]
-
Yen, P. M.,
Darling, D. S.,
Carter, R. L.,
Forgione, M.,
Umeda, P. K.,
and Chin, W. W.
(1992)
J. Biol. Chem.
267,
3565-3568[Abstract/Free Full Text]
-
Ribeiro, R. C. J.,
Kushner, P. J.,
Apriletti, J. W.,
West, B. L.,
and Baxter, J. D.
(1992)
Mol. Endocrinol.
6,
1142-1152[Abstract/Free Full Text]
-
Hörlein, A.,
Naar, A.,
Heinzel, T.,
Torchia, J.,
Gloss, B.,
Kurokawa, R.,
Ryan, A.,
Kamei, Y.,
Soderstrom, M.,
Glass, C.,
and Rosenfeld, M.
(1995)
Nature
377,
397-404[CrossRef][Medline]
[Order article via Infotrieve]
-
Chen, J.,
and Evans, R.
(1995)
Nature
377,
454-457[CrossRef][Medline]
[Order article via Infotrieve]
-
Onate, S.,
Tsai, S.,
Tsai, M.-J.,
and O'Malley, B.
(1995)
Science
270,
1354-1357[Abstract/Free Full Text]
-
Kamei, Y.,
Xu, L.,
Heinzel, T.,
Torchia, J.,
Kurokawa, R.,
Gloss, B.,
Lin, S.-C.,
Heyman, R.,
Rose, D.,
Glass, C.,
and Rosenfeld, M.
(1996)
Cell
85,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
-
Farsetti, A.,
Mitsuhashi, T.,
Desvergne, B.,
Robbins, J.,
and Nikodem, V. M.
(1991)
J. Biol. Chem.
266,
23226-23232[Abstract/Free Full Text]
-
Strait, K.,
Carlson, D.,
Schwartz, H.,
and Oppenheimer, J.
(1997)
Endocrinology
138,
635-641[Abstract/Free Full Text]
-
Farsetti, A.,
Desvergne, B.,
Hallenbeck, P.,
Robbins, J.,
and Nikodem, V. M.
(1992)
J. Biol. Chem.
267,
15784-15788[Abstract/Free Full Text]
-
Desvergne, B.,
Petty, K. J.,
and Nikodem, V. M.
(1991)
J. Biol. Chem.
266,
1008-1013[Abstract/Free Full Text]
-
Morioka, H.,
Tennyson, G. E.,
and Nikodem, V. M.
(1988)
Mol. Cell. Biol.
8,
3542-3545[Abstract/Free Full Text]
-
Higuchi, R.
(1989)
in
PCR Technology (Erlich, H. A., ed), pp. 61-70, W. H. Freeman and Co., New York
-
Modak, S. P.,
Principaud, E.,
and Spohr, G.
(1993)
Oncogene
8,
645-654[Medline]
[Order article via Infotrieve]
-
IJpenberg, A.,
Jeannin, E.,
Wahli, W.,
and Desvergne, B.
(1997)
J. Biol. Chem.
272,
20108-20117[Abstract/Free Full Text]
-
Le Ricousse, S.,
Gouilleux, F.,
Fortin, D.,
Joulin, V.,
and Richard-Foy, H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5072-5077[Abstract/Free Full Text]
-
Keller, H.,
Dreyer, C.,
Medin, J.,
Mahfoudi, A.,
Ozato, K.,
and Wahli, W.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2160-2164[Abstract/Free Full Text]
-
Wong, J., Shi, Y.-B., and Wolffe, A. P. (1995) Genes
Dev. 2696-2711
-
Lazar, M. A.,
Berrodin, T. J.,
and Harding, H. P.
(1991)
Mol. Cell. Biol.
11,
5005-5015[Abstract/Free Full Text]
-
Kim, H.-S.,
Crone, D. E.,
Sprung, C. N.,
Tillman, J. B.,
Force, W. R.,
Crew, M. D.,
Mote, P. L.,
and Spindler, S. R.
(1992)
Mol. Endocrinol.
6,
1489-1501[Abstract/Free Full Text]
-
Katz, R. W.,
and Koenig, R. J.
(1993)
J. Biol. Chem.
268,
19392-19397[Abstract/Free Full Text]
-
Schräder, M.,
Becker-André, M.,
and Carlberg, C.
(1994)
J. Biol. Chem.
269,
6444-6449[Abstract/Free Full Text]
-
Miyamoto, T.,
Suzuki, S.,
and DeGroot, L. J.
(1993)
Mol. Endocrinol.
7,
224-231[Abstract/Free Full Text]
-
Toyoda, N.,
Zavacki, A. M.,
Maia, A. L.,
Harney, J. W.,
and Larsen, P. R.
(1995)
Mol. Cell. Biol.
15,
5100-5112[Abstract]
-
Darling, D. S.,
Carter, R. L.,
Yen, P. M.,
Welborn, J. M.,
Chin, W. W.,
and Umeda, P. K.
(1993)
J. Biol. Chem.
268,
10221-10227[Abstract/Free Full Text]
-
Williams, G. R.,
Harney, J. W.,
Forman, B. M.,
Samuels, H. H.,
and Brent, G. A.
(1991)
J. Biol. Chem.
266,
19636-19644[Abstract/Free Full Text]
-
Brent, G. A.,
Williams, G. R.,
Harney, J. W.,
Forman, B. M.,
Samuels, H. H.,
Moore, D. D.,
and Larsen, P. R.
(1992)
Mol. Endocrinol.
6,
502-514[Abstract/Free Full Text]
-
Park, H.-Y.,
Davidson, D.,
Raaka, B. M.,
and Samuels, H. H.
(1993)
Mol. Endocrinol.
7,
319-330[Abstract/Free Full Text]
-
Bhat, M.,
Ashizawa, K.,
and Cheng, S.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7927-7931[Abstract/Free Full Text]
-
Katz, D.,
Reginato, M. J.,
and Lazar, M. A.
(1995)
Mol. Cell. Biol.
15,
2341-2348[Abstract]
-
Kurokawa, R., Yu, V. C.,
Näär, A.,
Kyakumoto, S.,
Han, Z.,
Silverman, S.,
Rosenfeld, M. G.,
and Glass, C. K.
(1993)
Genes Dev.
7,
1423-1435[Abstract/Free Full Text]
-
Yen, P. M.,
Ikeda, M.,
Wilcox, E. C.,
Brubaker, J. H.,
Spanjaard, R. A.,
Sugawara, A.,
and Chin, W. W.
(1994)
J. Biol. Chem.
269,
12704-12709[Abstract/Free Full Text]
-
Wahlström, G. M.,
Sjöberg, M.,
Andersson, M.,
Nordström, K.,
and Vennström, B.
(1992)
Mol. Endocrinol.
6,
1013-1022[Abstract/Free Full Text]
-
Medin, J. A.,
Minucci, S.,
Driggers, P. H.,
Lee, I. J.,
and Ozato, K.
(1994)
Mol. Cell. Endocrinol.
105,
27-35[CrossRef][Medline]
[Order article via Infotrieve]
-
Forman, B. M.,
Umesono, K.,
Chen, J.,
and Evans, R. M.
(1995)
Cell
81,
541-550[CrossRef][Medline]
[Order article via Infotrieve]
-
Katz, R. W.,
and Koenig, R. J.
(1994)
J. Biol. Chem.
269,
18915-18920[Abstract/Free Full Text]
-
Horwitz, K. B.,
Jackson, T. A.,
Bain, D. L.,
Richer, J. K.,
Takimoto, G. S.,
and Tung, L.
(1996)
Mol. Endocrinol.
10,
1167-1177[Abstract/Free Full Text]
-
Kurokawa, R.,
Soderstrom, M.,
Horlein, A.,
Halachmi, S.,
Brown, M.,
Rosenfeld, M.,
and Glass, C.
(1995)
Nature
377,
451-454[CrossRef][Medline]
[Order article via Infotrieve]
-
Chakravarti, D.,
LaMorte, V.,
Nelson, M.,
Nakajima, T.,
and Schulman, I.
(1996)
Nature
383,
99-103[CrossRef][Medline]
[Order article via Infotrieve]
-
Zamir, I.,
Zhang, J.,
and Lazar, M.
(1997)
Genes Dev.
11,
835-846[Abstract/Free Full Text]
-
Nawaz, Z.,
Tsai, M.-J.,
and O'Malley, B.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11691-11695[Abstract/Free Full Text]
-
Tong, G.-X.,
Jeyakumar, M.,
Tanen, M.,
and Bagchi, M.
(1996)
Mol. Cell. Biol.
16,
1909-1920[Abstract]
-
Renaud, J.-P.,
Rochel, N.,
Ruff, M.,
Vivat, V.,
Chambon, P.,
Gronemeyer, H.,
and Moras, D.
(1995)
Nature
378,
681-689[CrossRef][Medline]
[Order article via Infotrieve]
-
Henttu, P.,
Kalkhoven, E.,
and Parker, M.
(1997)
Mol. Cell. Biol.
17,
1832-1839[Abstract]
-
Strait, K.,
Zou, L.,
and Oppenheimer, J.
(1992)
Mol. Endocrinol.
6,
1874-1880[Abstract/Free Full Text]
-
Yarwood, N.,
Gurr, J.,
Sheppard, M.,
and Franklyn, J.
(1993)
J. Biol. Chem.
268,
21984-21989[Abstract/Free Full Text]
-
Wilson, T. E.,
Paulsen, R. E.,
Padgett, K. A.,
and Milbrandt, J.
(1992)
Science
256,
107-110[Abstract/Free Full Text]
-
Rastinejad, F.,
Perlmann, T.,
Evans, R.,
and Sigler, P.
(1995)
Nature
375,
203-211[CrossRef][Medline]
[Order article via Infotrieve]
-
Dollé, P.,
Fraulob, V.,
Kastner, P.,
and Chambon, P.
(1994)
Mech. Dev.
45,
91-104[CrossRef][Medline]
[Order article via Infotrieve]
-
Lefstin, J. A.,
and Yamamoto, K. R.
(1998)
Nature
392,
885-888[CrossRef][Medline]
[Order article via Infotrieve]
-
Krey, G.,
Mahfoudi, A.,
and Wahli, W.
(1995)
Mol. Endocrinol.
9,
219-231[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. N. Feige, L. Gelman, D. Rossi, V. Zoete, R. Metivier, C. Tudor, S. I. Anghel, A. Grosdidier, C. Lathion, Y. Engelborghs, et al.
The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor {gamma} Modulator That Promotes Adipogenesis
J. Biol. Chem.,
June 29, 2007;
282(26):
19152 - 19166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Flatt, L. L. Moroz, M. Tatar, and A. Heyland
Comparing thyroid and insect hormone signaling
Integr. Comp. Biol.,
December 1, 2006;
46(6):
777 - 794.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Schoonover, M. M. Seibel, D. M. Jolson, M. J. Stack, R. J. Rahman, S. A. Jones, C. N. Mariash, and G. W. Anderson
Thyroid Hormone Regulates Oligodendrocyte Accumulation in Developing Rat Brain White Matter Tracts
Endocrinology,
November 1, 2004;
145(11):
5013 - 5020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Helbing, K. Werry, D. Crump, D. Domanski, N. Veldhoen, and C. M. Bailey
Expression Profiles of Novel Thyroid Hormone-Responsive Genes and Proteins in the Tail of Xenopus laevis Tadpoles Undergoing Precocious Metamorphosis
Mol. Endocrinol.,
July 1, 2003;
17(7):
1395 - 1409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Dussault, M. Lin, K. Hollister, M. Fan, J. Termini, M. A. Sherman, and B. M. Forman
A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity
Mol. Cell. Biol.,
August 1, 2002;
22(15):
5270 - 5280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Guissouma, S. M. Dupre, N. Becker, E. Jeannin, I. Seugnet, B. Desvergne, and B. A. Demeneix
Feedback on Hypothalamic TRH Transcription Is Dependent on Thyroid Hormone Receptor N Terminus
Mol. Endocrinol.,
July 1, 2002;
16(7):
1652 - 1666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Weber, U. Zimmermann, H. Winter, A. Mack, I. Kopschall, K. Rohbock, H.-P. Zenner, and M. Knipper
Thyroid hormone is a critical determinant for the regulation of the cochlear motor protein prestin
PNAS,
February 20, 2002;
(2002)
52609899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rusch, L. Ng, R. Goodyear, D. Oliver, I. Lisoukov, B. Vennstrom, G. Richardson, M. W. Kelley, and D. Forrest
Retardation of Cochlear Maturation and Impaired Hair Cell Function Caused by Deletion of All Known Thyroid Hormone Receptors
J. Neurosci.,
December 15, 2001;
21(24):
9792 - 9800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Yen
Physiological and Molecular Basis of Thyroid Hormone Action
Physiol Rev,
July 1, 2001;
81(3):
1097 - 1142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Martín, M. L. Cortés, Pablo de Felipe, A. Farsetti, N. B. Calcaterra, and M. Izquierdo
Cancer Gene Therapy by Thyroid Hormone-mediated Expression of Toxin Genes
Cancer Res.,
June 1, 2000;
60(12):
3218 - 3224.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Zhang, X. Hu, and M. A. Lazar
A Novel Role for Helix 12 of Retinoid X Receptor in Regulating Repression
Mol. Cell. Biol.,
September 1, 1999;
19(9):
6448 - 6457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wu, P. Delerive, W. W. Chin, and T. P. Burris
Requirement of Helix 1 and the AF-2 Domain of the Thyroid Hormone Receptor for Coactivation by PGC-1
J. Biol. Chem.,
March 8, 2002;
277(11):
8898 - 8905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Weber, U. Zimmermann, H. Winter, A. Mack, I. Kopschall, K. Rohbock, H.-P. Zenner, and M. Knipper
Thyroid hormone is a critical determinant for the regulation of the cochlear motor protein prestin
PNAS,
March 5, 2002;
99(5):
2901 - 2906.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|